期刊文献+

抗CD_(25)单克隆抗体对肾移植受者末梢血淋巴细胞的影响 被引量:3

Effect of anti-CD_(25) monoclonal antibody on the lymphocyte in the peripheral blood of the recipients of kidney transplantation
原文传递
导出
摘要 目的 探讨抗CD2 5单克隆抗体 (舒莱 )对肾移植受者末梢血活化T细胞的抑制作用。 方法  4 6例肾移植受者随机分为舒莱治疗组 ( 2 3例 )和对照组 ( 2 3例 )。免疫抑制剂方案为新山地明胶囊 (Neoral)、硫唑嘌呤 (Aza)和泼尼松 (Pred) ,舒莱治疗组术前 2h和术后 4d各静脉滴注舒莱 2 0mg。应用流式细胞仪对 4 6例受者手术前后末梢血中不同表型淋巴细胞进行连续动态观察。  结果 与对照组比较 ,舒莱组活化T细胞 (CD+2 5)在用药后 2 4h明显下降 ,从用药前的 ( 17.0 0± 3.70 ) %降至 ( 3.30± 2 .4 3) % ,1周后降至 ( 2 .5 2± 1.0 9) % ,并在整个观察过程中呈低水平表达 (P <0 .0 1) ;淋巴细胞总数和T细胞 (CD+3 CD-19)总数无明显变化 ;B淋巴细胞 (CD-3 CD+19)、NK细胞 (CD-3 CD+16CD+56)和非HLA限制性细胞毒性T细胞 (CD+3 CD+16CD+56)未见明显升高。 结论 舒莱对活化T细胞有明显抑制作用 。 Objective To study the inhibition effect of anti-CD 25 monoclonal antibody (Simulect) to the activated T cells in the recipients of kidney transplantation. Methods Forty-six recipients of renal transplantation were randomly divided into therapeutic group with simulect (23 cases) and control group (23 cases).All recipients in both groups received immunosuppressive therapy with neoral,azatheoprine and predonine conventionally.The recipients in simulect group received additionally 20 mg simulect at 2h preoprative and 4d postoperative,respectively.Several phenotypes of lymphocyte in the peripheral blood of all recipients were observed sequentially with flow cystometer. Results Compared with the control group,the number of activated T cells(CD + 25 ) decreased significantly within 24h after the first dose in the patients who received simulect,and the level of the cells that expressed CD 25 was significantly lower than that of control during the whole observation( P <0.01).The total numbers of lymphocytes and T cells(CD + 3CD - 19 ) were unchanged;the numbers of B cells (CD - 3CD + 19 ),NK cells (CD - 3CD + 16 CD + 56 ) and non HLA restricted cytotoxic T cells (CD + 3CD + 16 CD + 56 ) were not increased. Conclusions Simulect inhibits the activated T cells effectively.The mechanism of inhibition is the clonal blockage rather than deletion.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2004年第11期731-733,共3页 Chinese Journal of Urology
关键词 肾移植 T细胞 末梢血 CD25单克隆抗体 抗C 受者 CD19 结论 总数 水平 Transplantation Kidney Monoclonal antibody CD 25
  • 相关文献

参考文献4

  • 1Waldmann TA.1992 Stohlman memorial lecture targeting the IL-2 receptor. Leukemia,1993,7(suppl 2):s151-s156.
  • 2Jones PT,Dear PH,Foote J,et al.Replacing the complementarity-mouse.Nature,1986,321:522-525.
  • 3Nashan B,Moore R,Amole P,et al.Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients.Lancet,1997,350:1193-1198.
  • 4Kahan BD,Rajagopalan PR,Hall ML,et al.Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab,A chimeric anti-interleukin-2-receptor monoclonal antibody.Transplantation,1999,67:276-284.

同被引文献33

  • 1Nashan B, Moore R, Amole P, et al.Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients[J]. Lancet, 1997, 350(9086):1193-1198.
  • 2Kahan BD, Rajagopalan PR. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody[J]. Transplantation, 1999, 67(2):276-284.
  • 3Sijpkens YW,Doxiadis II,Mallat M J,et al.Early versus late acute rejection episodes in renal transplantation.Transplantation 2003;75(2):204-208
  • 4Mulloy LL,Wright F,Hall ML,et al.Simulect reduces acute cellular rejection in renal allograft from cadaveric and living donors.Transplant Proc 1999;31:1210-1213
  • 5Kapic E,Becic F,Kusturica J.Basiliximab,mechanism of action and pharmacological properties.Med Arh 2004;58(6):373-376
  • 6Kovarik JM,Moore R,Wolf P,et al.Screening for basiliximab exposure-response relationships in renal allotransplantation.Clin Transplant 1999;13:32-38
  • 7Nashan B,Moore R,Amlot P,et al.Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients.Lancet 1997;350(9086):1193-1198
  • 8Kahan BD,Rajaqopalan PR,Hall M.Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab,a chimeric anti-interleukin-2-receptor monoclonal antibody.Transplantation 1999;67(2):276-284
  • 9Ando T,Tojimbara T,Sato S,et al.Efficacy of simulect induction therapy in ABO-incompatible kidney transplantation:a rapid steroid withdrawal protocol.Transplant Proc 2004;36(7):2182-2183
  • 10Vincenti F.Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patients.Transpl Int 2004;17(8):395-401

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部